CCM
ALNY icon

Cadian Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Cadian Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-130,243
Closed -$12.6M – 87
2014
Q4 		$12.6M Buy
130,243
+5,243
+4% +$486K 0.32% 58
2014
Q3 		$9.76M Buy
125,000
+65,000
+108% +$4.19M 0.26% 56
2014
Q2 		$3.79M Buy
+60,000
New +$3.57M 0.11% 70

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Cadian Capital Management's ALNY Position: Q1 2015 in Review

Cadian Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2015, closing a stake of 130,243 shares — an estimated $12.6M sold.

Cadian Capital Management first reported a position in ALNY in Q2 2014 and held it in 3 quarters. The position peaked at $12.6M in Q4 2014. 238 funds tracked by Wall St. Rank hold ALNY as of Q1 2015.

  • Cadian Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Cadian Capital Management sold 130,243 Alnylam Pharmaceuticals shares in Q1 2015, an estimated $12.6M.
  • Cadian Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 3 quarters.
  • Cadian Capital Management's Alnylam Pharmaceuticals position peaked at $12.6M in Q4 2014.
  • 238 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2015.

Based on Cadian Capital Management's 13F filing for Q1 2015, filed 14 May 2015.